Advanced

Anaplastic thyroid carcinoma: three protocols combining doxorubicin, hyperfractionated radiotherapy and surgery.

Tennvall, Jan LU ; Lundell, G; Wahlberg, Peter LU ; Bergenfelz, Anders LU ; Grimelius, L; Åkerman, Måns LU ; Hjelm Skog, A-L and Wallin, G (2002) In British Journal of Cancer 86(12). p.1848-1853
Abstract
Patients with anaplastic thyroid carcinoma can rarely be cured, but every effort should be made to prevent death due to suffocation. Between 1984 and 1999, 55 consecutive patients with anaplastic thyroid carcinoma were prospectively treated according to a combined regimen consisting of hyperfractionated radiotherapy, doxorubicin, and when feasible surgery. Radiotherapy was carried out for 5 days a week. The daily fraction until 1988 was 1.0 Gyx2 (A) and 1989-92 1.3 Gyx2 (B). Thereafter 1.6 Gyx2 (C) was administered. Radiotherapy was administered to a total target dose of 46 Gy; of which 30 Gy was administered preoperatively in the first two protocols (A and B), while the whole dose was given preoperatively in the third protocol (C). The... (More)
Patients with anaplastic thyroid carcinoma can rarely be cured, but every effort should be made to prevent death due to suffocation. Between 1984 and 1999, 55 consecutive patients with anaplastic thyroid carcinoma were prospectively treated according to a combined regimen consisting of hyperfractionated radiotherapy, doxorubicin, and when feasible surgery. Radiotherapy was carried out for 5 days a week. The daily fraction until 1988 was 1.0 Gyx2 (A) and 1989-92 1.3 Gyx2 (B). Thereafter 1.6 Gyx2 (C) was administered. Radiotherapy was administered to a total target dose of 46 Gy; of which 30 Gy was administered preoperatively in the first two protocols (A and B), while the whole dose was given preoperatively in the third protocol (C). The therapy was otherwise identical. Twenty mg doxorubicin was administered intravenously weekly. Surgery was possible in 40 patients. No patient failed to complete the protocol due to toxicity. In only 13 cases (24%) was death attributed to local failure. Five patients (9%) 'had a survival' exceeding 2 years. No signs of local recurrence were seen in 33 patients (60%); 5 out of 16 patients in Protocol A, 11 out of 17 patients in Protocol B, 17 out of 22 patients in Protocol C (P=0.017). In the 40 patients undergoing additional surgery, no signs of local recurrence were seen in 5 out of 9 patients, 11 out of 14 patients and 17 out of 17 patients, respectively (P=0.005). (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Neoplasm Recurrence, Middle Age, Male, Lung Neoplasms : secondary, Human, Female, Feasibility Studies, Doxorubicin : therapeutic use, Dose Fractionation, Combined Modality Therapy, Clinical Protocols, Carcinoma : therapy, Carcinoma : pathology, Carcinoma : mortality, Anthracycline : therapeutic use, Antibiotics, 80 and over, Aged, Local, Postoperative Care, Prospective Studies, Quality of Life, Survival Rate, Thyroid Neoplasms : mortality, Thyroid Neoplasms : pathology, Thyroid Neoplasms : therapy
in
British Journal of Cancer
volume
86
issue
12
pages
1848 - 1853
publisher
Nature Publishing Group
external identifiers
  • pmid:12085174
  • wos:000176739800003
  • scopus:0037125034
ISSN
1532-1827
DOI
10.1038/sj.bjc.6600361
language
English
LU publication?
yes
id
252b1123-0add-435c-b8df-75987f97e0ac (old id 109024)
alternative location
http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12085174&dopt=Abstract
date added to LUP
2007-07-19 10:55:09
date last changed
2017-11-12 03:21:18
@article{252b1123-0add-435c-b8df-75987f97e0ac,
  abstract     = {Patients with anaplastic thyroid carcinoma can rarely be cured, but every effort should be made to prevent death due to suffocation. Between 1984 and 1999, 55 consecutive patients with anaplastic thyroid carcinoma were prospectively treated according to a combined regimen consisting of hyperfractionated radiotherapy, doxorubicin, and when feasible surgery. Radiotherapy was carried out for 5 days a week. The daily fraction until 1988 was 1.0 Gyx2 (A) and 1989-92 1.3 Gyx2 (B). Thereafter 1.6 Gyx2 (C) was administered. Radiotherapy was administered to a total target dose of 46 Gy; of which 30 Gy was administered preoperatively in the first two protocols (A and B), while the whole dose was given preoperatively in the third protocol (C). The therapy was otherwise identical. Twenty mg doxorubicin was administered intravenously weekly. Surgery was possible in 40 patients. No patient failed to complete the protocol due to toxicity. In only 13 cases (24%) was death attributed to local failure. Five patients (9%) 'had a survival' exceeding 2 years. No signs of local recurrence were seen in 33 patients (60%); 5 out of 16 patients in Protocol A, 11 out of 17 patients in Protocol B, 17 out of 22 patients in Protocol C (P=0.017). In the 40 patients undergoing additional surgery, no signs of local recurrence were seen in 5 out of 9 patients, 11 out of 14 patients and 17 out of 17 patients, respectively (P=0.005).},
  author       = {Tennvall, Jan and Lundell, G and Wahlberg, Peter and Bergenfelz, Anders and Grimelius, L and Åkerman, Måns and Hjelm Skog, A-L and Wallin, G},
  issn         = {1532-1827},
  keyword      = {Neoplasm Recurrence,Middle Age,Male,Lung Neoplasms : secondary,Human,Female,Feasibility Studies,Doxorubicin : therapeutic use,Dose Fractionation,Combined Modality Therapy,Clinical Protocols,Carcinoma : therapy,Carcinoma : pathology,Carcinoma : mortality,Anthracycline : therapeutic use,Antibiotics,80 and over,Aged,Local,Postoperative Care,Prospective Studies,Quality of Life,Survival Rate,Thyroid Neoplasms : mortality,Thyroid Neoplasms : pathology,Thyroid Neoplasms : therapy},
  language     = {eng},
  number       = {12},
  pages        = {1848--1853},
  publisher    = {Nature Publishing Group},
  series       = {British Journal of Cancer},
  title        = {Anaplastic thyroid carcinoma: three protocols combining doxorubicin, hyperfractionated radiotherapy and surgery.},
  url          = {http://dx.doi.org/10.1038/sj.bjc.6600361},
  volume       = {86},
  year         = {2002},
}